Loading
A. Serretti, A. Lucca, C. Cusin, E. Smeraldi - Vol. 7, Marzo 2001, num.1
Testo Immagini Bibliografia Summary Riassunto Indice
Associazione di reboxetina nella depressione resistente
a SSRI
Effect of reboxetine augmentation in SSRI resistant patients
2 Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965;122:509.
3 Delgado PL, Miller HL, Salomon RM, Licinio J, Heninger GR, Gelenberg AJ, et al. Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants. Psychopharmacol Bull 1993;29:389-96.
4 Schatzberg AF, Schildkraut JJ. Recent studies on norepinephrine systems in mood disorders. In: Bloom FE, ed. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press 1994.
5 Kuevi V, Causon R, Dixson AF, Everard DM, Hall JM, Hole D, et al. Plasma amine and hormone changes in ‘post-partum blues’. Clin Endocrinol 1983;19:39-46.
6 Pandey GN, Dysken MW, Garver DL, Davis JM. Beta-adrenergic receptor function in affective illness. Am J Psychiatry 1979;136:675-8.
7 Checkley SA, Crammer JL. Hormone responses to methylamphetamine in depression: a new approach to the noradrenaline depletion hypothesis. Br J Psychiatry 1977;131:582-6.
8 Golden RN, Markey SP, Risby ED, Rudorfer MV, Cowdry RW, Potter WZ. Antidepressants reduce whole-body norepinephrine turnover while enhancing 6-hydroxymelatonin output. Arch Gen Psychiatry 1988;45:150.
9 Puech AJ, Lecrubier Y, Simon P. The role of norepinephrine in affective disorders. Encephale 1979;5:507-19.
10 De Paermentier F, Cheetham SC, Crompton MR, Katona CL, Horton RW. Brain beta-adrenoceptor binding sites in depressed suicide victims: effects of antidepressant treatment. Psychopharmacology 1991;105:283-8.
11 Maes M, Meltzer HY. The serotonin hypothesis of Major Depression. In: Bloom FE, ed. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press 1994.
12 Jaffe EH, De Frias V, Ibarra C. Changes in basal and stimulated release of endogenous serotonin from different nuclei of rats subjected to two models of depression. Neuroscience Letters 1993;162:157-60.
13 Vijayakumar M, Meti BL. Alterations in the levels of monoamines in discrete brain regions of clomipramine-induced animal model of endogenous depression. Neurochemical Res 1999;24:345-9.
14 Zangen A, Overstreet DH, Yadid G. High serotonin and 5-hydroxyindoleacetic acid levels in limbic brain regions in a rat model of depression: normalization by chronic antidepressant treatment. J Neurochemistry 1997;69:2477-83.
15 Bel N, Artigas F. Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse 1993;15:243-5.
16 Jacobs BL, Azmitia EC. Structure and function of the brain serotonin system. Physiol Rev 1992;72:165-229.
17 Baraban JM, Aghajanian GK. Noradrenergic innervation of serotonergic neurons in the dorsal raphe: demonstration by electron microscopic autoradiography. Brain Res 1981;204:1-11.
18 Peyron C, Luppi PH, Fort P, Rampon C, Jouvet M. Lower brainstem catecholamine afferents to the rat dorsal raphe nucleus. J Comp Neurology 1996;364:402-13.
19 Bel N, Artigas F. In vivo effects of the simultaneous blockade of serotonin and norepinephrine transporters on serotonergic function. Microdialysis studies. J Pharmacol Exp Ther 1996;278:1064-72.
20 Asberg M, Ringberger VA, Sjoqvist F, Thoren P, Traskman L, Tuck JR. Monoamine metabolites in cerebrospinal fluid and serotonin uptake inhibition during treatment with chlorimipramine. Clin Pharmacol Ther 1977;21:201-7.
21 Thomas DN, Nutt DJ, Holman RB. Sertraline, a selective serotonin reuptake inhibitor modulates extracellular noradrenaline in the rat frontal cortex. J Psychopharmacol 1998;12:366-70.
22 Cohen RM, Campbell IC, Cohen MR, Torda T, Pickar D, Siever LJ, et al. Presynaptic noradrenergic regulation during depression and antidepressant drug treatment. Psychiatry Res 1980;3:93-105.
23 Collis MG, Shepherd JT. Antidepressant drug action and presynaptic alpha-receptors. Mayo Clinic Proceedings 1980;55:567-72.
24 Prange AJ, Wilson IC, Lynn CW, Alltop LB, Stikeleather RA. L-tryptophan in mania: contribution to a permissive hypothesis of affective disorders. Arch Gen Psychiatry 1974;30:56.
25 Mongeau R, Blier P, de Montigny C. The serotonergic and noradrenergic systems of the hippocampus: their interactions and the effects of antidepressant treatments. Brain Res - Brain Res Rev 1997;23:145-95.
26 Nolen WA, Haffmans J. Treatment of resistant depression. Review on the efficacy of various biological treatments, specifically in major depression resistant to cyclic antidepressants. Int Clin Psychopharmacol 1989;4:217-28.
27 Schweitzer I, Tuckwell V Risk of adverse events with the use of augmentation therapy for the treatment of resistant depression. Drug Safety 1998;19:455-64.
28 Anonymous.
Practice guideline for major depressive disorder in adults. American Psychiatric Association.
Am J Psychiatry 1993;150:1-26.
29 Szegesi A, Wetzel H, Leal M, Hartter S, Hiemke C. Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety and tolerability data. J Clin Psychiatry 1996;57:257-64.
30 Massana J. Reboxetine versus fluoxetine: an overview of efficacy and tolerability. J Clin Psychiatry 1998;59(Suppl)14:8-10.
31 Montgomery SA. Chairman’s overview. The place of reboxetine in antidepressant therapy. J Clin Psychiatry 1998;59(Suppl)14:26-9.
32 Mucci M. Reboxetine: a review of antidepressant tolerability. J Psychopharmacol 1997;11:S33-7.
33 Dubini A, Bosc M, Polin V. Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning. J Psychopharmacol 1997;11:S17-23.
34 Hindmarch I. The effects of antidepressants on psychomotor function with particular reference to reboxetine. Eur Neuropsychopharmacol 1997;7(Suppl)1:S17-21; discussion S71-3.
35 Berzewski H, Van Moffaert M, Gagiano CA. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes. Eur Neuropsychopharmacol 1997;7(Suppl)1:S37-47; discussion S71-3.
36 Harkin A, Kelly JP, McNamara M, Connor TJ, Dredge K, Redmond A, et al. Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression. Eur J Pharmacol 1999;364:123-32.
37 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Washington DC: American Psychiatric Association, 1994.
38 Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-96.
39 Quitkin FM, Rabkin JG, Gross D, Stewart JW Identification of true drug response to antidepressants: use of pattern analysis. Arch Gen Psychiatry 1984;41:782-6.
40 Quitkin FM, Rabkin JG, Markowitz JM, Stewart JW, McGrath PJ, Harrison W. Use of pattern analysis to identify true drug response: a replication. Arch Gen Psychiatry 1987;44:258-64.
41 Quitkin FM. Placebos, Drug effects, and study design: a clinician guide. Am J Psychiatry 1999;156:829-36.
42 Massana J, Moller HJ, Burrows GD, Montenegro RM. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1999;14:73-80.